



RECEIVED

FEB 27 2002

Express Mail Label No.: EL844533606US

Date of Deposit: February 15, 2002

Attorney's Docket No.: C1039/7035 (HCL/MAT)

1501 CENTER STREET, SUITE 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ARTHUR M. KRIEG, ET AL.  
Filing Date: September 25, 2000  
Serial No.: 09/669,187  
Conf. No.: 2999  
For: IMMUNOSTIMULATORY NUCLEIC ACIDS  
Examiner: James Martinell  
Art Unit: 1633

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

AMENDMENT

Sir:

In the Specification

Please re-write the specification paragraphs as indicated below. A marked-up version of these paragraphs is attached hereto as Appendix A.

Please re-write the two paragraphs beginning on page 22, lines 24, as follows:

Figure 1A is a histogram of the expression of CD86 (Y-axis) by CD19+ cells following exposure of these cells to the oligonucleotides shown on the X-axis at a concentration of 0.15 µg/ml.

Figure 1B is a table with the data from Figure 1A.

Figure 1C is a histogram of the expression of CD86 (Y-axis) by CD19+ cells following exposure of these cells to the oligonucleotides shown on the X-axis at a concentration of 0.30 µg/ml.

Figure 1D is a table with the data from Figure 1C.

Please re-write the paragraph beginning on page 130, line 7, as follows:

To assess the ability of T-rich ODN to activate B cell proliferation, human PBMCs were stained with the cytoplasmic dye CFSE, incubated with five days with the indicated ODN at

594704.1